• Clozapine N-oxide (CNO) for Chemogenetic Workflows

  2026-08-31

  Clozapine N-oxide (CNO) enables reversible, circuit-level control of engineered GPCRs, making it useful for linking neuronal activity modulation to behavior and physiology. This practical guide translates a VTA–parabrachial nucleus anesthesia study into formulation, dosing, controls, and troubleshooting decisions for modern DREADD experiments.

• Wnt-C59: A Secretion-Centric Wnt Assay Strategy

  2026-08-30

  Wnt-C59 is a potent PORCN inhibitor for separating Wnt ligand production, trafficking, and pathway activation. This article connects its use in cancer biology with a mechanistic assay framework inspired by lithium-engineered exosomal Wnt10a research.

• ECL Western Blotting Substrate: Workflow Guide

  2026-08-29

  ECL Western Blotting Substrate (SKU K2187) is a luminol-based horseradish peroxidase detection reagent for nonradioactive Western blot assays using X-ray film or CCD imaging. It is intended for HRP chemiluminescence workflows and should not be used as a substitute for fluorescent or radioisotopic detection methods.

• Zoledronic Acid: Applied Cancer and Bone Workflows

  2026-08-29

  Build more reproducible cancer cell apoptosis assays and bone-disease studies with a workflow that treats solubility, nominal exposure, and endpoint timing as critical variables. This guide also shows how a recent γδT17-cell study can inspire orthogonal assay design without overstating evidence for Zoledronic Acid outside cancer and skeletal research.

• Regorafenib, RRM2, and ERK/E2F3 in Melanoma

  2026-08-28

  A 2024 iScience study identifies RRM2 as a downstream effector of Regorafenib in melanoma and connects its suppression to ERK/E2F3 signaling. The work combines functional cell assays, RNA sequencing, rescue experiments, and tumor studies to define a mechanistic basis for the compound’s anti-melanoma activity.

• Toremifene Workflow for Prostate Cancer Research

  2026-08-28

  Toremifene supports controlled estrogen-receptor modulation in hormone-responsive cancer research, with practical utility in cell-growth, migration, and signaling workflows. This guide connects dose-response assay design with the TSPAN18–STIM1 metastasis framework while clearly separating established evidence from testable research hypotheses.

• Calpain Inhibitor II, ALLM in Translational Cancer Research

  2026-08-27

  Calpain Inhibitor II, ALLM offers a practical way to interrogate cysteine-protease control of apoptosis and focal-adhesion biology. By connecting the FAISL–calpain 2–FAK mechanism in triple-negative breast cancer with leukemia and lymphoma models, this article outlines how translational researchers can use ALLM rigorously while accounting for its multi-protease profile.

• Bone Transport and TGF-β1 in Diabetic Foot Ulcers

  2026-08-27

  A 2026 rat study identifies TGF-β1/TGFBR1 activation as a mechanistic link between bone transport, angiogenesis, immune regulation, and diabetic foot ulcer repair. By combining proteomics with molecular, histological, and biochemical analyses, the work shows that pathway inhibition substantially weakens the healing response, while also defining important limits for translating the findings to pharmacological workflows.

• Talin1, Piezo1–YAP, and Atherosclerotic Inflammation

  2026-08-26

  A 2026 study identifies Talin1 as a mechanistic link between Piezo1-mediated calcium influx, YAP activation, and inflammatory endothelial responses under atherogenic stress. By combining an ApoE-deficient mouse model with human endothelial-cell experiments, the work suggests that Talin1 may be a more specific target for vascular anti-inflammatory research.

• Gastrodin, RAS–SIRT3, and Reactive Astrocytes

  2026-08-26

  A 2024 European Journal of Neuroscience study examined how gastrodin changes renin–angiotensin system and SIRT3 signaling in astrocytes exposed to activated microglia-conditioned medium. Its main contribution is a cell-to-cell inflammatory model linking AT1 signaling with astrocyte phenotype markers, inflammatory mediators, and neurotrophic responses, while azilsartan provided pharmacological support for an AT1-dependent mechanism.

• EGO-Like Complex Controls TOR in Neurospora

  2026-08-25

  The reference study identifies VTA and GTR2 as components of an amino acid-sensing branch that regulates TOR activity and vacuolar localization in Neurospora crassa. Its comparison of glucose conditions, knockout strains, live-cell imaging, inhibitor treatment, and co-immunoprecipitation provides a framework for connecting nutrient sensing, TORC1 organization, and circadian regulation.

• Losmapimod: p38 MAPK Assay Workflows

  2026-08-25

  Losmapimod enables more than a conventional p38 activity readout: researchers can pair kinase inhibition with activation-loop dephosphorylation assays to test conformationally driven signaling control. This workflow supports inflammation signaling modulation, vascular function improvement, hypertension research, and chronic obstructive pulmonary disease (COPD) research while keeping mechanistic claims experimentally testable.

• hiPSC Sensory Neurons Model HSV-1 Latency

  2026-08-24

  Oh et al. establish a scalable human model in which hiPSCs are rapidly differentiated into excitable sensory neurons that support HSV-1 latency and experimentally induced reactivation. The study combines infectious-virus, transcriptional, latency-associated transcript, and chromatin readouts, creating a useful platform for investigating neuron-intrinsic mechanisms that are difficult to resolve in animal or non-neuronal systems.

• Rocket-Like Nanomedicine Restores PDAC Stroma

  2026-08-23

  Fu et al. developed an acid-responsive, multistage nanomedicine that remodels pancreatic ductal adenocarcinoma stroma before releasing gemcitabine from a mesoporous silica core. In a PDAC mouse model, this stromal homeostasis-restoring strategy produced marked tumor regression without evident treatment-related side effects, while highlighting the translational challenges of moving from stromal ablation to controlled remodeling.

• BMPSB4 Activates Autophagy in Corticotroph PitNETs

  2026-08-22

  The 2024 ACS Pharmacology & Translational Science study identifies BMPSB4 as a BMP4-pathway agonist that suppresses corticotroph pituitary neuroendocrine tumor cells through SMAD1/5/9-dependent autophagy. Its integrated patient-sample, transcriptomic, ultrastructural, cellular, and in vivo evidence provides a mechanistic basis for investigating BMP4 signaling as a therapeutic strategy in Cushing’s disease.

448 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page